Modalis Therapeutics Corporation (Tokyo Mothers 4883) is developing precision genetic medicines through epigenetic gene modulation. Modalis is advancing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene expression or histone modification without the need for double- stranded DNA cleavage, gene editing or base editing. Modalis is headquartered in Tokyo with laboratories and R&D facilities in Cambridge,
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $25M
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Medical In... | medicalinc... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.04.2019 | Series B | $25M | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 05.11.2021 | Consolidated Financial Results for the Nine Months Ended Sep... | Consolidated Financial Results for the Nine months ended September 30, 2021 [Japanese GAAP] Novem... | marketscre... |
| 05.11.2021 | Notice Regarding the Recording of Non-Operating Income (Fore... | This document has been translated from the Japanese original for reference purposes only. In the ev... | marketscre... |
| 05.08.2021 | Modalis Therapeutics : Notice regarding the recording of non... | This document has been translated from the Japanese original for reference purposes only. In the ev... | marketscre... |
| 06.05.2021 | MODALIS THERAPEUTICS CORPORATION Modalis Therapeutics : Not... | This document has been translated from the Japanese original for reference purposes only. In the ev... | marketscre... |
| 29.03.2021 | MODALIS THERAPEUTICS CORPORATION Modalis Therapeutics : Add... | This document has been translated from the Japanese original for reference purposes only. In the ev... | marketscre... |
| 29.03.2021 | Modalis Therapeutics : Additional Information Regarding the ... | This document has been translated from the Japanese original for reference purposes only. In the ev... | marketscre... |